军械
发表于 2025-3-21 19:47:25
书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0164131<br><br> <br><br>书目名称Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0164131<br><br> <br><br>
ovation
发表于 2025-3-21 21:42:32
Jacqueline Schuldt,Helmut Niegemanns from nonresponders. FDG PET/CT can distinguish viable from the nonviable disease. Still, false positives do occur because of posttreatment inflammatory changes due to the uptake of FDG in macrophages and activated leukocytes. We present multiple case scenarios of FDG PET/CT in response assessment of esophageal and gastric malignancy.
爱花花儿愤怒
发表于 2025-3-22 01:50:15
http://reply.papertrans.cn/17/1642/164131/164131_3.png
Colonnade
发表于 2025-3-22 05:13:31
http://reply.papertrans.cn/17/1642/164131/164131_4.png
刚毅
发表于 2025-3-22 10:53:01
http://reply.papertrans.cn/17/1642/164131/164131_5.png
hurricane
发表于 2025-3-22 13:05:11
http://reply.papertrans.cn/17/1642/164131/164131_6.png
Mumble
发表于 2025-3-22 17:26:35
http://reply.papertrans.cn/17/1642/164131/164131_7.png
被诅咒的人
发表于 2025-3-22 23:10:54
18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncologyo overcome some of the limitations of CE-MRI. There has been significant development in the use of PET imaging for a number of use cases particularly in the field of neuro-oncology. In this chapter, we review examples of several PET Tracers in Treatment Response Evaluation in Neuro-oncology.
勤勉
发表于 2025-3-23 02:46:44
PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignase to neoadjuvant therapy and detecting recurrent disease. There are several advantages and limitations of using .F-FDG PET in the assessment of treatment response. This chapter illustrates clinical examples of .F-FDG PET/CT in the assessment of treatment response in hepatobiliary, gall bladder and pancreatic malignancies.
neoplasm
发表于 2025-3-23 06:43:46
http://reply.papertrans.cn/17/1642/164131/164131_10.png